FARE Clinical Trial Finder
Finding a Trial
The purpose of a clinical trial is to identify the most effective, safest treatment for a disease. Clinical trials are key steps in the U.S. Food and Drug Administration’s drug approval process. Participants can access cutting-edge therapies while playing a vital role in helping researchers develop new treatments.
Use the FARE Clinical Trial Finder to simplify your search for research studies that fit your needs:
- Fill out the filter menu below. Use keywords for a narrow search, or leave keywords blank for a broader search.
- Click the Search Trials button. Matching trial summaries will appear at right. Select LEARN MORE to view details.
- For more information, email or phone the site coordinator at the trial site nearest to you.
- We strongly recommend that you consult with your healthcare provider about any trials that interest you and refer to our terms of service below.
FARE Clinical Trial Finder searches studies listed on clinicaltrials.gov, a service of the U.S. National Institutes of Health that provides information on publicly and privately supported human clinical studies in all 50 states plus Washington, D.C., and in more than 190 countries and U.S. territories.
For Patients
All food allergy patients who can give informed consent themselves or through a legal representative are eligible to join the FARE Patient Registry. This worldwide study lets patients share their deidentified (anonymous) clinical data with the research community. Register today to help drive research forward.
For Researchers
Do you need volunteers or data for your clinical trial? Let the FARE Patient Registry help you. Contact us at registry@foodallergy.org to get started.
-
A Food Additive Removal Diet for Pediatric Eosinophilic Esophagitis
Prospective, pragmatic standard of care clinical trial comparing dietary therapies of standard dairy elimination diet alone (DED) to dairy elimination plus food additive elimination (FREE)
5 Years - 16 YearsLearn More -
Allergy to Neuromuscular Blocking Agents and Pholcodine Exposure
The main objective of this study is to compare pholcodine exposure in patients having presented with a perianaesthetic anaphylactic reaction to a NMBA (cases) to pholcodine exposure in matched anaesthetised patients with injection of NMBA, who did not present with an anaphylactic reaction (controls). The secondary objectives of the study are: - To compare anti-pholcodine IgE, anti-ammonium IV IgE and total IgE levels between the case and control groups. - To study the concordance between exposure to pholcodine in cases and controls, by means of a patient self-questionnaire on the one hand and, on the other hand, by...
2 Years and OverLearn More -
An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
This is a Phase 2, open-label, extension study to assess the safety and tolerability of AK002, given monthly for 8 doses.
18 Years - 80 YearsLearn More -
An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE)
This is a multicenter, double- blind extension study of Oral Budesonide Suspension (OBS) in adults and adolescents (11 to 55 years of age, inclusive) with Eosinophilic Esophagitis (EoE) who have completed participation in the SHP621-301 induction study (NCT02605837). The primary objective is to evaluate the maintenance of efficacy of OBS over 36 weeks. Maintenance of efficacy will be measured by the peak eosinophilic count and Dysphagia Symptom Questionnaire (DSQ) score.
11 Years - 55 YearsLearn More -
An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE)
The purpose of this study is to test the safety and effectiveness of Losartan potassium in subjects with Eosinophilic Esophagitis (EoE), both those with a connective tissue disorder (CTD) and those without a CTD.
5 Years - 25 YearsLearn More -
AR101 Real-World Open-Label Extension Study
This study is enrolling participants by invitation only. This is an open-label, safety extension study for subjects who participated in the ARC007 study.
4 Years - 18 YearsLearn More -
A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis
Background: - Omalizumab is an approved drug for the treatment of asthma by the Food and Drug Administration. - Researchers are now studying this drug in a double-blind placebo-controlled manner to assess efficacy in patients with idiopathic anaphylaxis (recurrent hypersensitive allergic episodes for which a cause is not identified). - The study will improve understanding of the mechanisms involved in anaphylactic reactions as a response to the downregulation (a decrease in the number of receptors on the surface of cells) in mast cell (a resident cell with several types of tissues) ...
18 Years - 70 YearsLearn More -
A Registry Study of 100 Thousand Cases of Pediatric Patients on Reduning Injection（a Chinese Medicine Injection）Used in Hospitals in China
This study was advocated by Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences in February 2018. The purpose of this study is to make a monitoring of adverse reactions in 100 thousand children aged 14 years and below to see whether Reduning injection is safe and the characteristic and mechanism of anaphylactic reaction used Reduning injection in hospitals in China.
N/A - 14 YearsLearn More -
Assessment of Cow's Milk-related Symptom Scoring Awareness Tool in Young Turkish Children
In this study the investigators aimed to evaluate diagnostic accuracy the scoring tool used to determine cow's milk protein allergy, the cow's milk related symptom score, is based on the gastrointestinal, respiratory system and dermatological symptoms being together in young Turkish children.
N/A - 1 YearLearn More -
A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
This is a Phase 2, double-blind, randomized, placebo-controlled study to assess the effects of AK002, given monthly for 4 doses. It is hypothesized that AK002 is more effective than placebo control (alternative hypothesis) in reducing the number of eosinophils per high power field (HPF) in gastric and/or duodenal biopsies before and after receiving AK002 or placebo versus no difference between AK002 and placebo control (null hypothesis).
18 Years - 80 YearsLearn More
The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.